FDA Brief

Warning letters Drugs

FDA warning letter to

Scientific Protein Laboratories, LLC

High riskIssued Oct 10, 2025Posted Nov 4, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Scientific Protein Laboratories over manufacturing failures in animal-derived APIs, including equipment particles and inadequate investigations.

What happened

FDA inspected the Waunakee, WI facility from April 21 to May 2, 2025. Investigators found grooves and scratches on an API-contact table used in pancrelipase processing, which may generate particles and contaminate API. FDA also found inadequate investigations of failed test results (out-of-specification) in stability testing and of viral-positive batches.

What FDA found

  1. Equipment surfaces that contact raw materials, intermediates, and API had grooves and scratches, and FDA found no adequate preventive maintenance plan, material evaluation, particle-removal details, or risk assessment for affected API batches.

    FD&C Act section 501(a)(2)(B)
  2. The company failed to adequately investigate failed assay results during stability testing of thyroid powder, and its revised sampling procedure could mask individually failing results for a narrow therapeutic index drug.

  3. The company investigated a lipase assay failure in distributed pancreatin lots but did not expand the investigation to other lots or notify customers as its procedure required.

  4. A 2023 residual limit failure investigation lacked adequate root cause analysis, and another residual limit failure occurred in 2024.

  5. For batches rejected after positive viral test results, the company did not adequately evaluate cleaning between contaminated batches, extend the investigation to all source material, or assess whether thyroid lots and infected pancreas material came from the same supplier.

What FDA wants

FDA asks the company to respond in writing within 15 working days with what it has done to correct the deviations and prevent recurrence; if it cannot complete actions, it must state why and give a completion schedule. FDA also requests retrospective batch reviews, process and equipment evaluation, validation and corrective action plans, and an independent assessment of its investigation system.

Who should pay attention

  • drugmakers using animal-derived APIs from this facility
  • companies buying pancrelipase, pancreatin, or thyroid powder
  • supplier quality teams managing viral contamination and particulate controls

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk